Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03651453 · ClinicalTrials.gov registry record · NA

OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings

A NA study of HIV Infections and Substance Abuse, sponsored by Yale University.

Completed
Registry status
NA
Development phase
164
Enrollment target
1
Study location

NCT03651453 is a NA study of HIV Infections and Substance Abuse that has completed, run by Yale University. The registered enrollment target is 164 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03651453, a NA study of HIV Infections and Substance Abuse, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
164 participants
Enrollment target
1
Study location

Study Summary

To develop and test the effect of a patient-centered HIV prevention decision aid on HIV pre-exposure prophylaxis (PrEP) uptake among women with substance use disorders (SUD) in treatment.

Interventions

  • BEHAVIORAL Standard care
  • BEHAVIORAL Decision aid

Study Locations (1)

Connecticut

  • Yale AIDS Program - New Haven

Trial Details

FieldValue
Enrollment Target 164 participants
Start Date 2018-10-15
Est. Completion 2020-06-11
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT03651453

The ClinicalTrials.gov registry entry for NCT03651453 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Standard care is the first listed.

NCT03651453 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT03651453 about?

NCT03651453 is a clinical study titled "OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings". To develop and test the effect of a patient-centered HIV prevention decision aid on HIV pre-exposure prophylaxis (PrEP) uptake among women with substance use disorders (SUD) in treatment.

What is the current status of trial NCT03651453?

This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2018-10-15. Estimated completion is 2020-06-11.

What conditions does trial NCT03651453 study?

This clinical trial studies the following conditions: HIV Infections, Substance Abuse.

What interventions are being tested in trial NCT03651453?

The interventions under investigation include: Standard care (BEHAVIORAL), Decision aid (BEHAVIORAL).

Who is sponsoring clinical trial NCT03651453?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03651453 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.